This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhdanova, I. V. Articles by Leclair, O. U. Search for Related Content PubMed PubMed Citation Articles by Zhdanova, I. V. Articles by Leclair, O. U. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Melatonin Treatment for Age-Related Insomnia

Department of Brain and Cognitive Sciences (I.V.Z., R.J.W., J.P.S.) and Clinical Research Center (I.V.Z., R.J.W., M.M.R., J.A.T., J.P.S., O.U.L.), Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

Address all correspondence and requests for reprints to: Dr. R. J. Wurtman, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139. E-mail: dick{at}mit.edu

Abstract

Older people typically exhibit poor sleep efficiency and reduced nocturnal plasma melatonin levels. The daytime administration of oral melatonin to younger people, in doses that raise their plasma melatonin levels to the nocturnal range, can accelerate sleep onset. We examined the ability of similar, physiological doses to restore nighttime melatonin levels and sleep efficiency in insomniac subjects over 50 yr old. In a double-blind, placebo-controlled study, subjects who slept normally (n = 15) or exhibited actigraphically confirmed decreases in sleep efficiency (n = 15) received, in randomized order, a placebo and three melatonin doses (0.1, 0.3, and 3.0 mg) orally 30 min before bedtime for a week. Treatments were separated by 1-wk washout periods. Sleep data were obtained by polysomnography on the last three nights of each treatment period. The physiologic melatonin dose (0.3 mg) restored sleep efficiency (P < 0.0001), acting principally in the midthird of the night; it also elevated plasma melatonin levels (P < 0.0008) to normal. The pharmacologic dose (3.0 mg), like the lowest dose (0.1 mg), also improved sleep; however, it induced hypothermia and caused plasma melatonin to remain elevated into the daylight hours. Although control subjects, like insomniacs, had low melatonin levels, their sleep was unaffected by any melatonin dose.

This article has been cited by other articles:

				R. F. Riemersma-van der Lek, D. F. Swaab, J. Twisk, E. M. Hol, W. J. G. Hoogendijk, and E. J. W. Van Someren Effect of Bright Light and Melatonin on Cognitive and Noncognitive Function in Elderly Residents of Group Care Facilities: A Randomized Controlled Trial JAMA, June 11, 2008; 299(22): 2642 - 2655. [Abstract] [Full Text] [PDF]

				A. J. Lewy, B. J. Lefler, J. S. Emens, and V. K. Bauer The circadian basis of winter depression PNAS, May 9, 2006; 103(19): 7414 - 7419. [Abstract] [Full Text] [PDF]

				S. A. Rivkees Rest-Activity Patterns in Children With Hypopituitarism Pediatrics, June 1, 2003; 111(6): e720 - 724. [Abstract] [Full Text] [PDF]